Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Net Income towards Common Stockholders: 2017-2025

Historic Net Income towards Common Stockholders for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $8.8 million.

  • Puma Biotechnology's Net Income towards Common Stockholders fell 56.47% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 28.66%. This contributed to the annual value of $23.2 million for FY2024, which is 7.47% up from last year.
  • Latest data reveals that Puma Biotechnology reported Net Income towards Common Stockholders of $8.8 million as of Q3 2025, which was up 51.05% from $5.9 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Net Income towards Common Stockholders peaked at $20.3 million during Q3 2024, and registered a low of -$44.7 million during Q3 2021.
  • For the 3-year period, Puma Biotechnology's Net Income towards Common Stockholders averaged around $5.7 million, with its median value being $5.8 million (2023).
  • Per our database at Business Quant, Puma Biotechnology's Net Income towards Common Stockholders spiked by 1,710.00% in 2023 and then crashed by 443.68% in 2024.
  • Over the past 5 years, Puma Biotechnology's Net Income towards Common Stockholders (Quarterly) stood at $4.2 million in 2021, then plummeted by 232.72% to -$5.6 million in 2022, then surged by 318.84% to $12.3 million in 2023, then decreased by 0.31% to $12.2 million in 2024, then slumped by 56.47% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $5.9 million for Q2 2025, and $3.0 million during Q1 2025.